Breaking Finance News

Inovio Pharmaceuticals Announces Positive Flu Vacccine Results

In a press release Monday, Inovio Pharmaceuticals (NYSE: INO) announced that in a preclinical study of its new influenza vaccine, it had achieved a 100 percent rate of success in animals.

The vaccine, made to vaccinate against an especially virulent strain of the flu virus, H7N9, was tested on animals and according to the release, “100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus.”

In the study, its DNA vaccine was administered twice, three weeks apart, to mice. The mice were then exposed to a lethal dose of the H7N9 virus 4 weeks after the second vaccination. The 10 mice remained healthy while the 10 in the control group who were not given the vaccine had significant morbidity dying 8 days after administration.

Dr. J. Joseph Kim, Inovio’s President and CEO, said,

“We need truly preemptive, broad protection against multiple known and new strains within existing families of viruses. Furthermore, history has shown that new viruses and virus subtypes do periodically emerge − H7N9 being just one recent example − and speed in creating a new vaccine will be of the essence in pandemic situations. Inovio is proving its abilities on both counts. This new preclinical data further validates the power of Inovio’s DNA vaccines to induce antigen-specific antibody and T-cell responses, which we have also demonstrated across other medical conditions such as pre-cancerous lesions and HIV.”

Disclosure: At the time of this writing, the author had no position in the equities mentioned.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.